

**GOTTFRIED E. KONECNY, M.D.
CURRICULUM VITAE**

PERSONAL HISTORY:

Medical Gynecologic Oncology
Division of Hematology/Oncology
Department of Medicine
University of California Los Angeles
100 UCLA Medical Plaza, Suite 550
Los Angeles, CA 90095
(310) 825-6194

UCLA Translational Oncology Research Laboratories
Gynecologic Oncology Research
Department of Medicine, University of California Los Angeles
2825 Santa Monica Blvd., Suite 200
Santa Monica, CA 90404
(310) 586-2652
gkonecny@mednet.ucla.edu

EDUCATION:

B.A.	1981
Gymnasium Schiller Schule, Hannover, Germany	
M.D.	1988
Universität zu Köln, Cologne, Germany	
Residency	1989-1996
Department of Obstetrics & Gynecology Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Klinikum der Universität München – Großhadern, Munich, Germany	
Postdoctoral Research Fellow	1998-2003
Division of Hematology-Oncology David Geffen School of Medicine at UCLA	
Fellowship	2004-2007
Gynecologic Oncology, Div. of Gynecologic Surgery Department of Obstetrics & Gynecology Mayo Clinic, Rochester, Minnesota	

LICENSURE:

Germany	1991
California Medical Board	2008

PROFESSIONAL EXPERIENCE:

Present Position

Professor in Residence Since 07/2017
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
(Primary Appointment)

Division of Gynecologic Oncology Since 01/2018
Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
(Secondary Appointment)

Previous Positions

Associate Professor in Residence 07/2011- 06/2017
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA

Assistant Professor in Residence 07/2008-06/2011
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA

Visiting Assistant Professor 11/2007-06/2008
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA

Adjunct Assistant Professor 07/2003-06/2005
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA

Attending Physician 07/1998-11/1998
Department of Obstetrics & Gynecology
Klinik und Poliklinik für Frauenheilkunde und
Geburtshilfe Klinikum der Universität München –
Großhadern, Munich, Germany

Staff Physician 11/1996-06/1998
Department of Obstetrics & Gynecology
Klinik und Poliklinik für Frauenheilkunde und

Geburtshilfe Klinikum der Universität München –
Großhadern, Munich, Germany

PROFESSIONAL ACTIVITIES:

Committee Service

Member, Peer-Review Group All-Ireland Cooperative Oncology Group (ICOG)	2010-Present
Member, Scientific Program Committee American Society of Clinical Oncology (ASCO)	2011
Gynecologic Oncology Tumor Boards University of California, Los Angeles	2011-Present
Member, Experimental Medicine Committee American Gynecologic Oncology Group (GOG)	2012-Present
Member, Data Safety Monitoring Board (DSMB) Jonsson Comprehensive Cancer Center University of California Los Angeles	2014-Present
Elected member, Cancer Research Group American Society of Clinical Oncology (ASCO)	2014-Present
Peer reviewer for the Department of Defense Ovarian Cancer Research Program, Congressionally Directed Medical Research Program	2015-Present
Advisor Food and Drug Administration (FDA) Advisory Meeting on New Drug Development for Ovarian Cancer (Washington, DC)	Sep 3 rd 2015
Peer reviewer for the NIH/NCI National Clinical Trials Network (NCTN) Core Correlative Sciences Committee, Congressionally Directed Medical Research	2015-Present
Data Safety Monitoring Committee Jonsson Comprehensive Cancer Center University of California Los Angeles	2015-Present
Promotions/Appointment Committee (MEDCAP) Department of Medicine UCLA University of California Los Angeles	2016-Present

Clinical Trials Planning Group 2018-Present
National Cancer Institute
National Institute of Health

Community Service

Santa Monica Parish Church 1999-Present
Santa Monica, California

Professional Associations

German Society of Obstetrics and Gynecology 1994-Present
German Cancer Society 1994-Present
American Society of Clinical Oncology (ASCO) 1995-Present
Bavarian Society of Obstetrics and Gynecology 1999-Present
Society of Gynecologic Oncology 2004-Present
Minnesota Medical Association 2004-Present
European Society of Medical Oncology 2007-Present
American Association of Cancer Research 2014-Present

Editorial Services

Gynecologic Oncology (ad hoc reviewer) 2001-Present
Cancer Chemotherapy and Pharmacology 2002-Present
(ad hoc reviewer)
Clinical Cancer Research (ad hoc reviewer) 2003-Present
Breast Cancer Research and Treatment 2003-Present
(ad hoc reviewer)
Cancer Epidemiology Biomarkers & Prevention 2003-Present
(ad hoc reviewer)
Clinical Breast Cancer (ad hoc reviewer) 2005-Present
Molecular Cancer Therapies (ad hoc reviewer) 2006-Present
Cancer Research (ad hoc reviewer) 2008-Present
Gyn Onc Research & Practice (Editor) 2013-Present
Frontiers in Molecular Medicine (Senior Editor) 2013-Present
German Journal of OB & GYN (Editor) 2015-Present
Journal of Clinical Oncology (ad hoc reviewer) 2016-Present
Journal of the National Cancer Institute (Editor) 2017-Present

HONORS AND SPECIAL AWARDS:

Stipend of the Ernst und Bertha Grimmke Stiftung 1991-2001
Düsseldorf, Germany

Habilitation - Ludwig Maximilians Universität 2002
München, Germany, Venia Legendi, University
Teaching Qualifications – Ph.D. equivalent

Feature Presentation, Society of Gynecologic Oncology (SGO)	03/2006
Track Leader, Scientific Program Committee American Society of Clinical Oncology (ASCO)	2012, 2013
UCLA Jonsson Cancer Center Award for Clinical Excellence	8/2012
Discussant Plenary Session; American Society of Clinical Oncology (ASCO)	6/2013
Elected Member of the Sudeto-German Academy of Sciences	07/2014
Joe V. Meigs Award at the Annual Meeting of the Society of Pelvic Surgeons (SPS)	10/2014
Elected Member Society of Pelvic Surgeons	11/2015
STOP Cancer Research Award 2016 Los Angeles, California	12/2016
Presidential Award Society of Gynecologic Oncology Annual Meeting 2017, Washington, D.C.	03/2017
Elected Member European Academy of Sciences and Arts	11/2018

RESEARCH GRANTS

Previous Funding:

Title of Grant: HER2 Signaling Pathways in Breast Cancer
Source: DOD Breast Cancer Research Program, DAMD 17-01-1-0181,
Amount: \$550,000
Duration of support: 1/2003-12/2006
Principal Investigator: Dennis J Slamon, MD
Role in project: Co-I

Title of Grant: Therapeutic Opportunities to Target Tumor Initiating Cells in
Solid Tumors
Source: California Institute for Regenerative Medicine (DR1-01477)
Amount: \$19,979,660/duration
Duration of Support: 12/2010-4/2015
Principal Investigator: Dennis J. Slamon, M.D., Ph.D.

Role in project: Co-I
Effort: 30%

Title of Grant: IGFR1-signaling in Ovarian Cancer
Source: Max Kade Foundation, New York
Amount: \$49,000
Duration of support: 03/2010-03/2011
Principal Investigator: Maike Ihnen, MD
Role in project: Co-PI

Title of Grant: Endometrial Cancer Research
Source: Patrick Petersilia Foundation
Amount: \$100,000
Duration of support: 12/2010-12/2011
Principal Investigator: Gottfried E. Konecny, MD
Role in project: PI
Effort: 10%

Title of Grant: WS962377
An Open Label Phase II Study of the Efficacy and Safety of PD0332991: A Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients with Recurrent Ovarian Cancer Demonstrating RB-Proficiency and low P16 Expression.
Source: Pfizer (Investigator Initiated Research)
Amount: \$226,524
Duration of support: 11/2011-12/2018
Principal Investigator: Gottfried E. Konecny, MD
Role in project: PI
Effort: 1%

Title of Grant: NIH Award No: 1R01CA172404
Identifying Prognostic Markers and Therapeutic Targets for Serous Ovarian Cancer
Source: NIH / USC Sub-Award
Amount: \$10,068/year
Duration of support: 07/2013-06/2018
Principal Investigator: Susan Ramus, PhD
Role in project: Co-I
Effort: 4%

Title of Grant: Targeting Breast Cancer Progenitor Cells with a Notch 3 Antibody Drug Conjugate (BC1334104)

Source: DOD Breast Cancer Research Program Breakthrough Award
Amount: \$11,790/year
Duration of support: 09/2014-08/2017
Principal Investigator: Sara Hurvitz, MD
Role in project: Co-PI
Effort: 5%

Current Funding:

Title of Grant: Endometrial Cancer Molecularly Targeted Therapy Consortium
Source: The V Foundation - 2019 KYCF Cancers that Affect Women
Amount: \$250, 000 per year
Duration of support: 06/2019-05/2023
Principal Investigator: Angeles Secord, M.D.
Role in project: Co-PI
Effort: 5%

Title of Grant: An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a CDK4/6 Inhibitor in Selected Patients with Recurrent Ovarian or Endometrial Cancer (Investigator Initiated Research)
Source: Eli Lilly and Company
Amount: \$250, 000,-
Duration of support: 04/2019-04/2023
Principal Investigator: Gottfried E. Konecny, M.D.
Role in project: PI
Effort: 3%

Title of Grant: MISP Ovarian Cancer IST
A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype determined by NanoString Gene Expression Profiling. (Investigator Initiated Research)
Source: Merck
Amount: \$692,870
Duration of support: 12/2016-11/2019
Principal Investigator: Gottfried E. Konecny, M.D.
Role in project: PI
Effort: 3%

Title of Grant: New Treatment Strategies for Cervical Cancer
Development of novel preclinical models for cervical cancer

Source: drug screening
Debra and Gray Fournier Cervical Cancer Foundation
Amount: \$240,000,-
Duration of support: 07/2017-12/2020
Principal Investigator: Gottfried E. Konecny, M.D.
Role in project: PI
Effort: 3%

Title of Grant: Comprehensive preclinical studies to identify synergistic effects of combining PARP inhibitors with novel targeted therapies
Source: The Julie and Bruce Goldsmith Family Initiative for New Frontiers in Ovarian Cancer Research
Amount: \$100,000,-
Duration of support: 07/2018-12/2020
Principal Investigator: Gottfried E. Konecny, M.D.
Role in project: PI
Effort: 3%

Title of Grant: Precision Medicine in Ovarian Cancer: Using Single Cell Analysis
Source: Cancer Research Fund Alliance
Amount: \$149,929-
Duration of support: 02/01/2017 – 01/31/2020
Principal Investigator: Boris Winterhoff, M.D.
Role in project: Co-I
Effort: 3%

Title of Grant: Clinical Precision Medicine Based on Single Cell Analysis
Source: University of Minnesota Office of the Vice President of Research Grand Challenges
Amount: \$160,500,-
Duration of support: 01/01/2019 – 12/31/2020
Principal Investigator: Boris Winterhoff, M.D.
Role in project: Co-I
Effort: 3%

Leadership Responsibilities in Clinical Trials:

National Cancer Institute Clinical Trial: NCT00718523
TRIO14: A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type

1 receptor (IGF-1R) to first line chemotherapy in patients with optimally debulked (< 1cm) epithelial ovarian cancer.

(Role: Global Principal Investigator)

2011-Present

National Cancer Institute Clinical Trial: NCT00719212

TRIO15: A multicenter open label phase II study of the efficacy and safety of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second line therapy in patients with recurrent platinum sensitive ovarian cancer.

(Role: Global Principal Investigator)

2011-Present

National Cancer Institute Clinical Trial: NCT01379534

A Phase II, Open-Label, Non-Randomized, Multi-Center Study to Evaluate the Efficacy of Oral TK1258 as Second-Line Therapy in Patients with Either FGFR2 Mutated or Wild-Type Advanced and/or Metastatic Endometrial Cancer.

(Role: Global Principal Investigator)

2012-Present

National Cancer Institute Clinical Trial: NCT01536743

An Open Label Phase II Study of the Efficacy and Safety of PD0332991: A Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients with Recurrent Ovarian Cancer Demonstrating RB-Proficiency and low P16 Expression.

(Role: National Principal Investigator)

2013-Present

National Cancer Institute Clinical Trial: NCT03732950

A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype determined by NanoString Gene Expression Profiling.

(Role: National Principal Investigator)

2017-Present

National Cancer Institute Clinical Trial: NCT03574779

Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer (OPAL).

(Role: National Co-Principal Investigator)

2018-Present

LECTURES AND PRESENTATIONS:

8/1997 XV Akademische Tagung deutschsprechender Hochschullehrer in der Gynäkologie und Geburtshilfe
 “Immuntherapie des metastasierten Mammakarzinoms durch T-Zellaktivierende bispezifische Antikörper (bsAK)”
 Luzern, Switzerland

- 10/1998 2nd International European Breast Cancer Conference
“Randomised Adjuvant Trial Comparing Two Dose Intensities of
Epirubicin and Cyclophosphamide (EC) in High-Risk Breast Cancer”
Florence, Italy
- 7/1999 XVII Akademische Tagung deutschsprechender Hochschullehrer in der
Gynäkologie und Geburtshilfe
“Multiple Drug Effect Analyse von rhuMAb4D5 (Herceptin) und
verschiedenen Zytostatikaklassen an c-erbB-2 überexprimierenden
Mammakarzinom In Vitro”
Kloster Seeon, Germany
- 10/1999 5th International Symposium on Biological Therapy of Cancer
“Preclinical and Clinical Studies of Combinations of Chemotherapy with
the p53 Tumor Suppressor Gene for Ovarian Cancer”
Munich, Germany
- 2/2001 Annual Meeting of the Delaware Society of Clinical Oncology
“Herceptin and Novel Chemotherapy Combinations in Breast Cancer,
Clinical Implications of Drug Interactions and HER2 Testing”
Wilmington, DE
- 5/2001 37th Annual Meeting of the American Society of Clinical Oncology
“HER-2/neu Gene Amplification and Response to Paclitaxel in Patients
with Metastatic Breast Cancer”
San Francisco, CA
- 6/2001 Division of Hematology-Oncology, Dartmouth University
“New Strategies in the Treatment of HER-2/neu-Positive Breast Cancer”
Dartmouth, NH
- 7/2001 4th Pan-European Cancer Symposium
“HER-2/neu Gene Amplification and Response to Paclitaxel”
Prag, Tschechien
- 3/2002 Cleveland Clinic, Department of Medicine
“HER2 in the Treatment of Breast Cancer”
Cleveland, OH
- 7/2001 25th Anniversary of the Piedmont Oncology Association Spring Meeting
“Trastuzumab in the Treatment of HER2-Positive Metastatic Breast
Cancer: Implications of Drug Interactions and HER2 Testing”
Greensboro, NC
- 4/2002 93rd Annual Meeting of the American Association of Cancer Research

- “Therapeutic Advantage of a Dual Tyrosine Kinase Inhibitor (GW2016) in Combination with Chemotherapy Drugs or Trastuzumab Against Human Breast Cancer Cells with HER2 Overexpression”
San Francisco, CA
- 6/2002 Second Annual International Symposium on Translational Research in Oncology
“Steroid Hormone Receptors and HER2 in Breast Cancer”
Laguna Niguel, CA
- 7/2002 18th UICC International Cancer Congress
“Herceptin® in the Treatment of HER2-Positive Breast Cancer”
Oslo, Norway
- 6/2002 3rd International Meeting of the Breast Cancer International Research Group (BCIRG)
“Topoisomerase-II-alpha as a Predictive Marker in Breast Cancer”
Anaheim, CA
- 4/2004 University of Michigan, Ann Arbor
“Role of HER2 and EGFR in Breast Cancer”
Ann Arbor, MI
- 6/2004 Rush-Presbyterian – St. Luke’s Medical Center, Chicago
“Role of HER2 and EGFR in Breast Cancer”
Chicago, IL
- 6/2004 Scripps Institute, San Diego
“New Tools in the Prognostication of Breast Cancer”
La Jolla, CA
- 7/2004 Washington University, St. Louis
“Herceptin and Novel Chemotherapy Combinations in Breast Cancer, Clinical Implications of Drug Interactions and HER2 Testing”
St. Louis, MO
- 7/2004 International Symposium on Diagnostics and Therapy of Breast Cancer
“Targeting HER2 and EGFR in Breast Cancer”
Munich, Germany
- 12/2004 University of Minnesota – Mayo Clinic, Research Retreat
“Role of HER2 and EGFR in Endometrial Cancer”
Minneapolis, MN
- 5/2005 Annual Susan G. Komen Foundation, Race for the Cure Lecture
“Updates in the Treatment of Breast Cancer”

Boise, ID

- 5/2005 Amgen, Research and Development
“Biomarkers in Breast Cancer, Are We Re-Inventing the Wheel”
Thousand Oaks, CA
- 6/2005 Department of Defense Breast Cancer Research Program, Era of Hope Meeting
“Biomarkers in breast cancer, gene expression profiles as prognostic markers”
Philadelphia, PA
- 3/2006 Society of Gynecologic Oncology, Annual Meeting 2006,
“Activity of lapatinib (GW572016) a novel dual kinase inhibitor in endometrial cancer cells”
Palm Springs, CA
- 6/2006 Rush University Chicago, Grand Rounds,
“Targeted therapies in breast cancer”,
Chicago, IL
- 6/2006 University of Hannover, Hannover, Grand Rounds:
“Translational Research in Gynecologic Oncology”,
Hannover, Germany
- 9/2006 University of Regensburg, Grand Rounds,
“HER2 and EGFR inhibition in breast and endometrial cancer”
Regensburg, Germany
- 9/2006 Humboldt University Berlin, Grand Rounds,
“Epidermal growth factor receptor inhibitors in gynecologic oncology”,
Berlin, Germany
- 12/2006 San Antonio Breast Cancer Symposium 2006,
“HER2 gene amplification and response to dose dense therapy”,
San Antonio, TX,
- 3/2007 University of Southern California, Department of Obstetrics and Gynecology, Grand Rounds,
“Research in endometrial and ovarian cancer involving HER2, EGFR, and Src”,
Los Angeles, California
- 3/2007 University of Michigan, Department of Breast Medical Oncology, Grand Rounds: “Updates in the treatment of breast cancer, HER2/EGFR

- inhibitors”,
Ann Arbor, Michigan
- 5/2007 University of Utah, Department of Obstetrics and Gynecology Grand Rounds: “Translational Research in Gynecologic Oncology: Lessons from HER2”,
Salt Lake City, Utah
- 5/2007 International Gynecologic Society 2007,
“Lessons from targeting HER2 in breast cancer for treatments of endometrial cancer”, Mayo Clinic Rochester, MN
- 10/2007 Translational Oncology Research Meeting 2007,
“HER2 and Hormone Receptor Signaling Cross-talk in Breast Cancer”
Dublin, Ireland
- 3/2008 University of Hamburg, Department of Gynecologic Oncology, Grand Rounds: “Updates in the treatment of breast cancer, HER2/EGFR inhibitors”,
Hamburg, Germany
- 6/2008 Era of Hope DOD Breast Cancer Meeting 2008,
“Prognostic and Predictive Gene Expression Signatures in Breast Cancer”,
Baltimore, Maryland
- 1/2009 Scripps Cancer Center Grand Rounds,
“New Developments in targeting HER2 in Breast Cancer ”,
Scripps Institute, La Jolla, CA
- 3/2009 Cleveland Clinic Grand Rounds,
“Updates in the treatment of breast cancer, HER2/EGFR inhibitors”,
Cleveland, OH
- 5/2009 University of Erlangen ,
“New Targeted Therapies for Ovarian Cancer”,
Kloster Banz, Germany
- 9/2009 JCCC PI3K Round Table, UCLA,
“Targeting PI3K in Ovarian Cancer”,
Los Angeles, California
- 11/2009 Mayo Clinic, Department of Obstetrics and Gynecology
“Targeting IGF/IGFR1 Signaling in Ovarian Cancer”,
- 2/2010 University of South Florida
“Targeting IGF/IGFR1 Signaling in Ovarian Cancer”

- 9/2010 JCCC PI3K Round Table, UCLA,
“Targeting PI3K in Endometrial and Ovarian Cancer”,
Los Angeles, California
- 4/2011 University of Dublin
“Targeting IGF/IGFR1 Signaling in Ovarian Cancer”,
Dublin, Ireland
- 6/2011 American Society of Clinical Oncology
“Molecular Classification of Ovarian Cancer”
Chicago, Illinois
- 6/2011 Translational Research in Oncology (CCO)
“Novel Targeted Therapies in in Ovarian Cancer”
Chicago, Illinois
- 8/2011 Best of ASCO
“Recent Advanced in the Treatment of Gynecologic Malignancies”
Seattle, Washington
- 9/2011 University of British Columbia
“Molecular Classification of Ovarian Cancer and its Therapeutic
Implications”
- 10/2011 Japanese Society of Clinical Oncology
“Novel Targeted Therapies for Ovarian Cancer”
Nagoya, Japan
- 10/2011 University of Kyoto
“Novel Molecular Classification of Ovarian Cancer”
Kyoto, Japan
- 3/2012 Adelson Medical Research Foundation
“Molecular Characterization of Ovarian Cancer and the Therapeutic
Implications”
Las Vegas, NV
- 4/2012 Mayo Clinic
“Integrative Translational Research Approaches for Gynecologic Cancer”
Mayo Clinic, Rochester, Minnesota
- 6/2012 American Society of Clinical Oncology
“Gynecologic Cancer, Poster Discussion Session, Discussion”
Chicago, MI

- 12/2012 Shanghai Jiao Tong University
“Molecular Characterization of Ovarian Cancer”
Shanghai, China
- 6/2013 American Society of Clinical Oncology
“Prognostic relevance of gene signatures in high-grade serous ovarian carcinoma.”
Chicago, MI
- 6/2013 American Society of Clinical Oncology, Plenary Session
“Plenary Session: Discussion of GOG240 Bevacizumab in recurrent or persistent cervical cancer”
Chicago, MI
- 12/2013 Shanghai Jiao Tong University
“New Treatment Approaches in Cervical Cancer”
Shanghai, China
- 2/2014 University of Halle, Germany
“Ovarian Cancer Heterogeneity and it’s Therapeutic Implications”
Halle, Germany
- 9/2014 European Society of Medical Oncology
“Phase II study of dovitinib as second-line therapy in recurrent endometrial cancer.”
Madrid, Spain
- 10/2014 Sudeto-German Academy of Sciences
“Recent Advances in the Treatment of Women’s Cancers”
Munich, Germany
- 11/2014 Society of Pelvic Surgeons
“Molecular Classification of high Grade Serous Ovarian Cancer”
Tampa, Florida
- 9/2015 Food and Drug Administration, Washington ,D.C.
Advisory Meeting to the FDA
“workshop: Development of new clinical trial endpoints for an accelerated drug approval process in ovarian cancer”
Washington, D.C.
- 11/2015 Society of Pelvic Surgeons
“Molecular characterization of primary peritoneal cancer”
San Francisco, California
- 12/2015 Shanghai Jiao Tong University

“New Treatment Approaches in Ovarian Cancer”
Shanghai, China

- 03/2017 Annual Meeting on Women’s Cancer 2017
Society of Gynecologic Oncology
“Rucaparib in Patients with Relapsed Primary Platinum-Sensitive High
Grade Serous Ovarian Cancer”
Washington, D.C.
- 05/2017 Annual Cancer Research Symposium 2017
University of Minnesota
“From Cell Line Panel to Patient Stratification – A Model for Translational
Research”
Minneapolis, MN
- 10/2017 Society of Pelvic Surgeons Annual Meeting 2017
“Using Genomics for Patient Stratification in Endometrial Cancer”
Fairhope, AL
- 01/2018 Gynecology and Obstetrics 2018 - Berlin
“Molecular Characterization of Ovarian and Endometrial Cancer and its
Therapeutic Implications”
Berlin, Germany
- 04/2018 University of New South Wales Sydney
“Molecular Profiling of Ovarian Cancer for Patient Stratification – A
Model for Translational Research”
Sydney, Australia
- 05/2018 OncLive – State of the Science Summit
“The Role of PARP Inhibitors in the Treatment of Ovarian Cancer”
Los Angeles, CA
- 06/2018 American Society of Clinical Oncology Symposium
“Can PARP Inhibitor Resistance be predicted – What is the Clinical
Impact? Potential Strategies Used to Overcome Mechanisms of
Resistance”
Chicago, IL

PUBLICATION/BIBLIOGRAPHY

RESEARCH PAPERS

RESEARCH PAPERS (PEER REVIEWED)

RESEARCH PAPERS – PEER REVIEWED

1. **Konecny G**, Nestle-Kramling C, Untch M. Use of G-CSF in dose-intensified chemotherapy of breast cancer with FEC (500/75/500 mg/m² KO) in the adjuvant and metastatic situation. *Gynakol Geburtshilfliche Rundsch* 33(1):301-2, 1993
2. Untch M, Nestle-Kramling C, **Konecny G**, Harbeck N, Funke I, Kimmig R, Hepp H. Prognostic value of tumor cells in bone marrow in breast cancer. *Gynakol Geburtshilfliche Rundsch* 33(1):308-10,1993
3. Untch M, Sevin BU, Untch A, **Konecny G**, Nestle-Kramling C, Korell M, Hepp H. Testing chemosensitivity of cancer cell lines and gynecologic tumors with the ATP assay. *Gynakol Geburtshilfliche Rundsch* 33(1):311-3, 1993
4. Billing AG, Frohlich D, **Konecny G**, Schildberg FW, Machleidt W, Fritz H, Jochum M. Local serum application: restoration of sufficient host defense in human peritonitis. *Eur J of Clin Invest* 24(1):28-35, 1994
5. **Konecny G**, Frank M, Kahlert S, Untch M, Hepp H. Retrospective analysis of dose intensity of epirubicin in breast cancer. *Gynakol Geburtshilfliche Rundsch* 40(3-4):145-52, 2000
6. **Konecny G**, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H, Untch M. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. *Gynecol Oncol* 77(2):258-263, 2000
7. **Konecny G**, Pegram M, Untch M, Thomssen C, Jänicke F, Hepp H, Slamon D. HER-2/neu as a predictive marker in breast cancer. *Geburtshilfe und Frauenheilkunde* 60:609-619, 2000
8. Pegram M, **Konecny G**, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/ overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. *Cancer Treat Res* 103:57-75, 2000

9. **Konecny G**, Untch M, Slamon DJ, Beryt M, Kahlert S, Felber M, Langer E, Lude S, Hepp H., Pegram M. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine, or vinorelbine in breast cancer cell lines and tumor samples. *Breast Cancer Res Treat* 67:223-233, 2001
10. **Konecny G**, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M. Association of Urokinase-type Plasminogen Activator and its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer. *Clin Cancer Res* , 7(6):1743-9, 2001
11. **Konecny G**, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. *Clin Cancer Res* 7(8):2448-57, 2001
12. **Konecny G**, Fritz M, Untch M, Lebeau A, Felber M, Lude S, Beryt M, Hepp H, Slamon D, Pegram M. HER-2/neu overexpression and In Vitro chemosensitivity to CMF and FEC in primary breast cancer. *Breast Cancer Res Treat* 69: 53-63, 2001
13. Ebeling FG, Stieber P, Untch M, Nagel D, **Konecny GE**, Schmitt UM, Fateh-Moghadam A, Seidel D. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. *Br J Cancer*. 2002 Apr 22;86(8):1217-22.
14. **Konecny G**, Slamon DJ. HER2 testing and correlation with efficacy of trastuzumab therapy. *Oncology* (Huntingt) 16(11):1576-1578, 2002
15. **Konecny GE**, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. *J Natl Cancer Inst* 95(2):142-53, 2003
16. **Konecny GE** , Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. *Clin Cancer Res* 10(5):1706-16, 2004
17. **Konecny GE**, Pegram MD. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. *Oncology* (Williston Park) 18(14;12):32-6, 2004

18. Pegram MD*, **Konecny GE***, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. *J Natl Cancer Inst* 96(10):739-49, 2004 (*Shared first authorship)
19. **Konecny GE**, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Mobus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Janicke F, Slamon DJ. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. *J Natl Cancer Inst* 96(15):1141-51, 2004
20. Stemmler HJ, Salat C, Lindhofer H, Menzel H, Untch M, Kahlert S, **Konecny G**, Sauer H, Ledderose G, Heinemann V, Kolb HJ. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. *Anticancer Res* 25(4):3047, 2005
21. Ryan BM*, **Konecny GE***, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. *Ann Oncol* 17(4):597-604, 2006 (*Shared first authorship)
22. **Konecny GE**, Pegram M, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Gilmer T, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER2-overexpressing and trastuzumab treated breast cancer cells. *Cancer Res* 66(3):1630-9, 2006
23. **Konecny GE**, Venkatesan N, Yang G, Dering J, Ginther G, Finn R, Rahmeh R, Schoenberg Fejzo M, Toft T, Jiang SW, Slamon DJ, Podratz KC. Activity of Lapatinib a Novel HER2 and EGFR Dual Kinase Inhibitor in Endometrial Cancer Cells. *Br J Cancer* 98(6):1076-84, 2008
24. **Konecny GE**, Mariani A, Keeney GA, Thomas B, Riehle D, Murphy L, Neuper C, Jones M, Dowdy SC, Wang HJ, Morin P, Podratz KC. Claudin-3 and Claudin-4 expression in serous papillary, clear cell, and endometrioid endometrial cancer. *Gynecol Oncol* 109(2):263-9, 2008
25. Gutierrez J, **Konecny GE**, Hong K, Burges , Henty T, Lambiais P, Meng G. A new ELISA for use in a three-ELISA system to assess the amount of VEGF splice variants and VEGF110 in ovarian cancer tumors. *Clinical Chemistry* 54(3):597-601, 2008

26. Jones MB, Neuper C, Clayton A, Mariani A, **Konecny GE**, Thomas B, Keeney GA, Hartmann L, Podratz KC. Folate Receptor Alpha expression in “High Risk” Endometrial Cancer. *Int J Cancer* 123(7):1699-703, 2008
27. **Konecny GE**, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, Jones M, Neuper N, Thomas B, Muderspach L, Riehle D, Wang HJ, Dowdy S, Podratz KC, Press MF. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. *Br J Cancer* 100(1):89-95, 2009
28. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner Ch, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, **Konecny GE**. Intensive Dose-dense Compared with Conventionally Scheduled Preoperative Chemotherapy for High-risk Primary Breast Cancer. *J Clin Oncol* 27(18):2938-45, 2009
29. **Konecny GE**, Glas R, Dering J, Manivong K, Qi J, Finn RS, Guorong E, Hong K, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ. Activity of the Multi-Kinase Inhibitor Dasatinib against Ovarian Cancer Cells. *Br J Cancer* 101(10):1699-708, 2009
30. Huszar M, Pfeifer M, Schirmer U, Kiefel H, **Konecny GE**, Ben-Arie A, Edler L, Münch M, Müller-Holzner E, Jerabek-Klestil S, Abdel-Azim S, Marth C, Zeimet AG, Altevogt P, Fogel M. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. *J Pathol* 220(5):551-61, 2009
31. **Konecny GE**, Untch M, Pauletti G, Apple S, Wang HJ, Moebus V, Muck B, Kuhn W, Lück HJ, Thomssen C, Pegram MD, Slamon DJ. Association between HER2, TOP2A and Response to Anthracycline-based Preoperative Chemotherapy in High-Risk Primary Breast Cancer. *Breast Cancer Res Treat* 120(2):481-9, 2010
32. Möbus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, **Konecny GE**, Untch M. Intense Dose-dense Sequential Chemotherapy with Epirubicin, Paclitaxel and Cyclophosphamide Compared with Conventionally Scheduled Chemotherapy in High-risk Primary Breast Cancer (4+ LN): Mature results of an AGO-phase-III study. *J Clin Oncol* 28(17):2874-80, 2010

33. von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, **Konecny G**, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. *Breast Cancer Res Treat* 125(1):145-56, 2011
34. **Konecny GE**, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. *Clin Cancer Res* 17(6):1591-602, 2011
35. Santiskulvong C, **Konecny GE**, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. *Clin Cancer Res* 17(8):2373-84, 2011
36. Untch M, von Minckwitz G, **Konecny GE**, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann MW, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Lebeau A, Loibl S, Fasching PA; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis. *Ann Oncol* 22(9):1999-2006, 2011
37. Untch M, Fasching PA, **Konecny GE**, von Koch F, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Lebeau A, Loibl S, von Minckwitz G; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery. *Ann Oncol* 22(9):1988-98, 2011

38. Fejzo MS, Ginther C, Dering J, Anderson L, Venkatesan N, **Konecny G**, Karlan B, Slamon DJ. Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK. *Genes Chromosomes Cancer* 50(6):434-41, 2011
39. Untch M, Fasching PA, **Konecny GE**, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. *J Clin Oncol* 29(25):3351-7, 2011
40. Untch M, Blohmer J, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W; Hilfrich J, Huober J, Jackisch C, Kaufmann M, **Konecny GE**, Denkert C, Nekljudova V, Mehta K, Loibl S. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol* 30(15):1796-804, 2012
41. Ditsch N, Vodermaier A, Hinke A, Burghardt S, Lenhard M, Löhrs B, Toth B, von Koch F, Kahlert S, Bauerfeind I, **Konecny GE**, Loibl S, von Minckwitz G, Untch M. Dose-dense Intensified Sequential Versus Conventionally-dosed Anthracycline and Taxane-containing Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer. *Anticancer Res* 32(8):3539-45, 2012
42. Goode EL, Derycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, Winterhoff B, Phelan CM, Schildkraut JM, Weber RP, Iversen E, Berchuck A, Sutphen R, Birrer MJ, Hampras S, Preus L, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Song H, Tyrer J, Pharoah PP, **Konecny G**, Sellers TA, Ness RB, Sucheston LE, Odunsi K, Hartmann LC, Moysich KB, Knutson KL. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. *PLoS One* 8(1):e53903, 2013
43. **Konecny GE**, Emerging strategies for dual inhibition of HER2-positive breast cancer. *Curr Opin Obstet Gynecol* 25(1):55-65, 2013
44. **Konecny GE**, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Graus Porta D, Anderson L, Shi MM, Yovine A, Slamon DJ. Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib

(TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells.
Mol Cancer Ther 12(5):632-42, 2013

45. Pharoah P, Tsai Y, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Price M, Fridley BL, ..., **Konecny GE**, ..., Pearce CL, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro A, Gayther SA, Schildkraut JM, Sellers TA. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.
Nature Genetics 45(4):362-70, 2013
46. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, ..., **Konecny GE**, ..., Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench, Dunning AM. Multiple independent TERT variants associated with telomere length and risks of breast and ovarian cancer.
Nature Genetics 45(4):371-84, 2013
47. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, ..., **Konecny GE**, ..., Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
Nature Comm 4:1627, 2013
48. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, ..., **Konecny GE**, ..., Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Pearce CL. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.
Nature Comm 4:1628, 2013
49. Cicek MS, Koestler DC, Fridley BL, Kalli KR, Armasu SM, Larson MC, Wang C, Vierkant RA, Rider DN, Klotzle B, **Konecny GE**, Winterhoff BJ, Shridhar V, Fan JB, Visscher DW, Olson JE, Bibikova M, Chien J, Cunningham JM, Goode EL. Epigenome-wide Analysis Identifies a Profile of DNA Methylation Associated with Clear Cell Ovarian Cancer. *Hum Mol Genet* 22:3038-4, 2013
50. Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginter C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong H, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, **Konecny GE**. Therapeutic Potential of the Poly (ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer.
Molecular Cancer Ther 12(6):1002-15, 2013

51. Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, Winterhoff BJ, Hamidi H, **Konecny GE**, Chien J, Bibikova M, Fan JB, Kalli KR, Lindor NM, Fridley BL, Pharoah PP, Goode EL. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. *Sci Rep* 2014;4:4026
52. Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Hanusch C, Jackisch C, Kümmel S, Huober J, Denkert C, Hilfrich J, **Konecny GE**, Fett W, Stickeler E, Harbeck N, Mehta KM, Nekljudova V, von Minckwitz G, Untch M. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. *Breast Cancer Res Treat* 2014;144(1):153-62
53. Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, **Konecny GE**. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. *Clin Cancer Res* 2014;20(11):2947-58
54. Wang C, Cicek MS, Charbonneau B, Kalli KR, Armasu SM, Larson MC, **Konecny GE**, Winterhoff B, Fan JB, Bibikova M, Chien J, Shridhar V, Block MS, Hartmann LC, Visscher DW, Cunningham JM, Knutson KL, Fridley BL, Goode EL. Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer. *Cancer Res* 2014;74(11):3084-91
55. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, **Konecny GE**, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. *J Clin Invest* 2014;124(6):2611-25
56. Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, ..., **Konecny G**, ..., Chenevix-Trench G, Pharoah PD, Gayther SA, Ness RB, Odunsi K, Sucheston LE, Knutson KL, Goode EL. Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunol Res* 2014 (4):332-40
57. Untch M, **Konecny GE**, Paepke S, von Minckwitz G. Current and future role of neoadjuvant therapy for breast cancer. *Breast* 2014;14. pii: S0960-9776

58. **Konecny GE**, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL. Prognostic and Therapeutic Relevance of Molecular Subtypes in High Grade Serous Ovarian Cancer. *J Natl Cancer Inst* 2014;106 (10):dju249
59. Mackey JR, Ramos-Vazquez M, Lipatov O, McCarthy N, Krasnozhan D, Semiglazov V, Manikhas A, Gelmon KA, **Konecny GE**, Webster M, Hegg R, Verma S, Gorbunova V, Abi Gerges D, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. *J Clin Oncol* 2015;33(2):141-8.
60. He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, Palmer JS, Roche DK, Hollier BG, Westbrook TF, Hamidi H, **Konecny GE**, Winterhoff B, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Tinker AV, Gilks CB, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. *Oncogene* 2015 doi: 10.1038 [Epub ahead of print]
61. **Konecny GE**, Finkler N, Garcia AA, Lorusso D, Lee D, Rocconi R, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomized, open-label, two-group, two-stage, phase 2 study. *Lancet Oncol* 2015;16(6):686-94.
62. Elias KM, Emori MM, Papp E, MacDuffie E, **Konecny GE**, Velculescu VE, Drapkin R. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. *Gynecol Oncol* 2015;139(1):97-103.
63. Winterhoff BJN, Hamidi H, Wang C, Kalli KR, Fridley, Dering J, Chen HW, Cliby WA, Wang HJ, Dowdy SC, Gostout BS, Keeney GS, Goode EL, **Konecny GE**. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expressions signatures. *Gynecol Oncol* 2016;141(1):95-100.

64. Vogel RI, Pulver T, Heilmann W, Mooneyham A, Mullany S, Zhao X, Shahi M, Richter J, Klein M, Chen L, Ding R, **Konecny G**, Kommos S, Winterhoff B, Ghebre R, Bazzaro M. USP14 is a Predictor of Recurrence in Endometrial Cancer and a Molecular Target for Endometrial Cancer Treatment. *Oncotarget* 24;7(21):30962-76. doi:10.186322016
65. Wang C, Winterhoff BJ, Kalli KR, Block MS, Armasu SM, Larson MC, Chen HW, Keeney GL, Hartmann LC, Shridhar V, **Konecny GE**, Goode EL, Fridley BL. Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer. *Br J Cancer* 2016;14:114(12):1412-20
66. Way GP, Rudd J, Wang C, Hamidi H, Fridley BL, **Konecny GE**, Goode EL, Greene CS, Doherty JA. Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes. *G3 (Bethesda)* 2016 pii: g3.116.033514. doi: 10.1534
67. Raghavan R, Hyter S, Pathak HB, Godwin AK, **Konecny G**, Wang C, Goode EL, Fridley BL. Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer. *BMC Genomics* 2016;17(1):811
68. Mesko S, Sandler K, Cohen J, **Konecny G**, Steinberg M, Kamrava M. Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies. *Int J Gynecol Cancer* 2017;27(2):403-408
69. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, **Konecny GE**, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. *Lancet Oncology* 2017;18(1):75-87
70. Kommos S, Winterhoff B, Oberg A, **Konecny GE**, Wang C, Riska SM, Fan JB, Maurer MJ, April C, Shridhar V, Kommos F, du Bois A, Hilpert F, Mahner S, Baumann K, Schroeder W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC, Pfisterer J. Bevacizumab may differentially improve ovarian cancer outcome in patients with

proliferative and mesenchymal molecular subtypes.
Clin Cancer Res 2017;23(14):3794-3801

71. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Isabelle Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen L, Provencher D, Ma L, Brenton JD, **Konecny GE**, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. *Gynecologic Oncology* 2017 pii: S0090-8258(17)31260
72. Coleman RL, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway R, Gancedo AM, Fong P, Goh J, O'Malley DM, Armstrong D, Garcia-Donas J, Swisher EM, Floquet A, **Konecny GE**, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA. Rucaparib maintenance treatment for recurrent ovarian cancer after response to platinum therapy (ARIEL3): a phase 3, international, randomised, double-blind trial. *Lancet* 2017 pii: S0140-6736(17)32440-6
73. Torres D, Kumar A, Wallace SK, Bakkum-Gamez JN, **Konecny GE**, Weaver AL, McGree ME, Goode EL, Cliby WA, Wang C. Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer. *Gynecol Oncol* 2017;147(3):503-508
74. Möbus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, **Konecny GE**, Untch M, Kurbacher C. Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial. *Ann Oncol* 2018;1;29(1):178-185.
75. Torres D, Wang C, Kumar A, Bakkum-Gamez JN, Weaver AL, McGree ME, **Konecny GE**, Goode EL, Cliby WA. Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability. *Gynecol Oncol*. 2018;150(2):227-232.

76. Hellweg R, Mooneyham A, Chang Z, Shetty M, Emmings E, Iizuka Y, Clark C, Starr T, Abrahante JH, Schütz F, **Konecny G**, Argenta P, Bazzaro M. RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment. *Horm Cancer*. 2018 doi: 10.1007/s12672-018-0337-6.
77. Campos MP, Cohen M, Von Euw E, Velculescu V, Kujak JL, Conklin D, Hallberg D, Slamon DJ, Elvin J, **Konecny GE**. BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition. *JCO Precision Oncology* 2018 doi: 10.1200/PO.18.00025.
78. Lin K, Harrell M, Oza A, Oaknin A, Ray-Coquard I, Tinker A, Helman E, Radke M, Say C, Lan-Vo L, Mann E, Isaacson J, Maloney L, O'Malley D, Chambers S, Kaufmann S, Scott C, **Konecny GE**, Coleman R, Sun J, Giordano H, Brenton J, Harding T, McNeish I, Swisher E. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. *Cancer Discov* 2018 Nov 13. pii: CD-18-0715.
79. Papp E, Hallberg, **Konecny GE**, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Conklin D, Kinose Y, White JR, Press MF, Drapkin R, Easwaran H, Baylin S, Slamon D, Velculescu VE, Scharpf RB. Integrated Genomic, Epigenetic, and Expression Analyses of Ovarian Cancer Cell Lines. *Cell Reports* 2018 25(9):2617-2633.
80. Zhang H, Wang S, Cacalano N, Zhu H, Liu Q, Xie M, Kamrava M, **Konecny G**, Jin S. Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines. *Sci Rep* 2019;9(1):2111.
81. Winterhoff B, Kommos S, Heitz F, **Konecny GE**, Dowdy SC, Mullany SA, Park-Simon TW, Baumann K, Hilpert F, Brucker S, du Bois A, Schröder W, Burges A, Shen S, Wang J, Tourani R, Ma S, Pfisterer J, Aliferis CF. Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions. *AMIA Annu Symp Proc* 2018;2018:1093-1102
82. Prendergast EN, Holman LL, Liu AY, Lai TS, Campos MP, Fahey JN, Wang X, Abdelaal N, Rao JY, Elvin JA, Moore M, Konecny GE, Cohen JG. Comprehensive Genomic Profiling of Recurrent

Endometrial Cancer: Implications for Selection of Systemic Therapy
Gynecologic Oncology in press

RESEARCH PAPERS (NON-PEER REVIEWED)

RESEARCH PAPERS – NON-PEER REVIEWED

1. **Konecny G.** Training in Obstetrics and Gynecology in Europe". Joint Meeting of the ECOG and RCOG, London, 10th and 11th December 1993. *Gynakol Geburtshilfliche Rundsch* 34(3):184-5, 1994
2. Lück HJ, Thomssen Ch, du Bois A, Lisboa BW, Untch M, Kühnle H, **Konecny G**, Jänicke F, Meerpohl HG, Lindner CH, Hecker D, Diergarten C. Interim analysis of a phase II study of Epirubicin and Paclitaxel as first line therapy in patients with metastatic breast cancer. *Semin Oncol* 23(1):33-36, 1996
3. Untch M, Böttcher B, Kahlert S, **Konecny G**, Nestle-Krämling C, Bauerfeind J, Hepp H. Medikamente in der Therapie des Mammakarzinoms. *Medizinische Genetik* 2(10): 262-265, 1998
4. Crohns C, **Konecny G**, Blokh E, Kurbacher C, Cree I, Untch M. Hat die prätherapeutische Chemosensitivitätstestung beim Mammakarzinom einen Stellenwert? *Gynäkologe* 32:705-709, 1999
5. Pegram M, Lopez A, **Konecny G**, Slamon D. Trastuzumab and chemotherapy; drug interaction and synergy. *Semin Oncol* 27 (6) suppl 11:21-25, 2000
6. **Konecny G**, Pegram M, Slamon D. Docetaxel and trastuzumab: a combination with clinical relevance. *Onkologie* 23(suppl 6): 10-12, 2000
7. Untch M, Von Koch F, Crohns C, Sobotta K, Kahlert S, **Konecny G**, Hepp H. Dose-dense and sequential strategies in adjuvant breast cancer therapy. *Oncology* (Huntingt) 15(5 Suppl 7):14-20, 2001
8. **Konecny G**, Pegram M. Docetaxel/Platinum/Trastuzumab Combinations in HER2-Overexpressing Metastatic Breast Cancer: Preliminary Results on Safty and Efficacy. *Cancer Conference Highlights* 5 (3):4-6, 2001
9. **Konecny G**, Pegram M. Trastuzumab plus anti-VEGF antibody in breast cancer: Preclinical rational and clinical data. *Biological Therapy of Breast Cancer* 4(2) 8-11, 2002

10. Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janat MM, Untch M, **Konecny G**, Bruckner HW, Cree IA. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Recent Results Cancer Res;161:221-30, 2003
11. Untch M, Ditsch N, Langer E, Kurbacher C, Crohns C, **Konecny G**, Kahlert S, Bauerfeind I, Hepp H. Chemosensitivity testing in gynecologic oncology-dream or reality? Recent Results Cancer Res;161:146-58, 2003
12. **Konecny GE**, Pegram M. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. *Oncology (Williston Park)* 18(14 Suppl 12):32-6, 2004
13. Rueckert S, Ruehl I, Kahlert S, **Konecny G**, Untch M. A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab. Expert Opin Biol Ther 5(6):853-66, 2005
14. Untch M, Loibl S, **Konecny GE**, von Minckwitz G. Neoadjuvant clinical trials for the treatment of primary breast cancer: the experience of the German study groups. *Curr Oncol Rep* 14(1):27-34, 2012

CHAPTERS

1. Untch M, Funke I, Nestle-Krämling C, **Konecny G**, Böttcher B, Schneider P, Hagen D, Fields K. Selektion von neuen Prognoseparametern für adjuvante systemische Maßnahmen beim Mammakarzinom (Quantitative Messung von Proteasen im Primärtumor, Nachweis von Tumorzellen im Knochenmark). In: Aktuelle Onkologie 87. Praktische Onkologie 5. Schmid L, Wilmanns W (Eds.), Zuckschwerdt-Verlag München, 104-118, 1995
2. Lück HJ, Thommsen C, du Bois A, Untch M, Lisboa BW, Kühnle H, Jänicke F, Meerpohl HG, **Konecny G**, Lindner C, Hecker D, Diergarten K. Interims-Analyse einer Phase-II-Studie der Kombination Epirubicin/Paclitaxel in der First-line-Therapie des metastasierten Mammakarzinoms. In: Taxol in der Kombinationstherapie. du Bois A, Klaassen U, Lück HJ, Diergarten K (Eds.), Zuckschwerdt-Verlag München, 90-100, 1996
3. Untch M, **Konecny G**, Nestle-Krämling C, Bauerfeind I. Neoadjuvante Chemotherapie, Indikation, Kontraindikation, Prognose.

In: Aktuelle adjuvante Therapie des Mammakarzinoms, Siebert W (Ed.), Hans Marseille Verlag München, 39-42, 1996

4. **Konecny G**, Bischoff J, Eiermann W, Funke I, Gabius S, Gutschow K, Jänicke F, Kuhn W, Salat C, Sattler D, Sauer H, Untch M. Adjuvante Therapie des Mammakarzinoms. In Mamma Karzinome. Empfehlungen zur Diagnostik, Therapie und Nachsorge 6. Tumorzentrum München (Ed.), 126-144, 1997
5. Eiermann W, Jänicke F, **Konecny G**, Possinger, Sauer HJ, Thomssen C, Tigges, Untch M. Systemische Therapie metastasierter Mammakarzinome. In Mamma Karzinome. Empfehlungen zur Diagnostik, Therapie und Nachsorge 6. Tumorzentrum München (Ed.), 126-144, 1997
6. Pegram MD, **Konecny G**, Slamon DJ. Use of HER2 for predicting response to breast cancer therapy. In Diseases of the Breast, Vol 3, Harris JR, Lippman ME (Eds.), Lippincott Williams, Cedar Knolls, NJ, 1999
7. Untch M, **Konecny G**, Nestle-Krämling, Bauerfeind I. Neoadjuvante Chemotherapie – Indikation, Kontraindikation, Prognose. Aktuelle adjuvante Therapie des Mammakarzinoms, Siebert (Ed.), Hans Marseille Verlag 39-42, 1999
8. Crohns C, **Konecny G**, Blokh E, Kurbacher C, Cree I, Untch M. Hat die prätherapeutische Chemosensitivitätstestung beim Mammakarzinom einen Stellenwert? In Gynäkologe 32:705-709, 1999
9. **Konecny G**, Untch M, Pegram M. Herceptin® in der Therapie des metastasierten Mammakarzinoms In Gynäkologe 32:624-631, 1999
10. Kahlert S, Untch M, **Konecny G**, Hepp H. Zytostatische Therapie des metastasierten Mammakarzinoms. Neue Substanzen und innovative Kombinationen. In Gynäkologe 32:614-623, 1999
11. Untch M, Kahlert S, **Konecny G**, Nestle-Krämling C, Crohns C, Bauerfeind I, Richter A, Hepp H. Die präoperative Chemotherapie beim operablen Mammakarzinom. In: Akt. Onkol., du Bois A, Bokemeyer C, Gatzemeier U, Kreienberg R, Kühnle H (Eds), 107:34-44, Zuckschwerdt Verlag 1999.
12. Untch M, **Konecny G**, Nestle-Krämling, Bauerfeind I. Neoadjuvante Chemotherapie Indikation, Kontraindikation, Prognose. In Aktuelle adjuvante Therapie des Mammakarzinoms, Siebert W (Ed.), Hans Marseille Verlag, 39-42, 1999

13. **Konecny G**, Untch M, Crohns C, Pegram M, Slamon D. c-erbB-2-Überexpression und Herceptin in der Therapie des Mammakarzinoms. In *Diagnostik und Therapie des Mammakarzinoms. State of the Art*, Untch M, Konecny G, Sittek H, Kessler M, Reiser M, Hepp H (Eds.), 378-387, 2000
14. Pegram M, **Konecny G**, Slamon DJ. HER2/neu and the clinical development of Herceptin. In *Breast Cancer Management*, Nabholz JM, Tonkin K, Aapro M, Buzdar A (Eds.). Martin Dunitz, 197-208, 2000
15. **Konecny G**, Kahlert St, Sattler D, Kuhn W, Untch M. Neoadjuvante Chemotherapie beim Mammakarzinom. In *Diagnostik und Therapie des Mammakarzinoms. State of the Art*, Untch M, **Konecny G**, Sittek H, Kessler M, Reiser M, Hepp H (Eds.), 323-335, 2000
16. Pegram MD, **Konecny GE**, and Slamon DS. The Molecular and Cellular Biology of HER2/neu Gene Amplification/Overexpression and the Clinical Development of Herceptin (Trastuzumab) Therapy for Breast Cancer. Gradishar, William J & Wood, William C. (Eds.) *Advances in Breast Cancer Management*, Kluwer Academic Publishers, Boston, MA, 57-76, 2000
17. **Konecny G**, Bauerfeind I, Untch M. Dosisintensivierte adjuvante Chemotherapie des primären Mammakarzinoms. In *Diagnostik und Therapie des Mammakarzinoms. State of the Art*, Untch M, **Konecny G**, Sittek H, Kessler M, Reiser M, Hepp H (Eds.), 336-346, 2000
18. Bauerfeind I, **Konecny G**, Untch M. Die endokrine Therapie beim postmenopausalen Mammakarzinom. In *Diagnostik und Therapie des Mammakarzinoms. State of the Art*, Untch M, **Konecny G**, Sittek H, Kessler M, Reiser M, Hepp H (Eds), 312-322, 2000
19. Pegram M, **Konecny G**, Buller R, Runnebaum I, Slamon DJ, Nielsen LL, Horowitz J, Karlan BY. Preclinical and phase I clinical studies of combinations of chemotherapy with recombinant adenovirus containing full-length, human p53 tumor suppressor gene cDNA for p53-mutant ovarian cancer. In *Textbook of Ovarian Cancer*, Jacobs I, Hudson CN, Shepherd J, Oram D, Blackett A, Luelsley D, Berchuck A (Eds.), Oxford University Press 287-393, 2001
20. Crohns C, Kahlert S, **Konecny G**, von Koch F, Bauerfeind I, Nestle-Krämling C, Sobotta K, Blokh E, Untch M. Wie aggressiv darf oder sollte die adjuvante Mammakarzinomtherapie sein? In *Aktuelle Onkologie*, 113:19-29, Zuckschwerdt Verlag, 2001

21. Untch M, Sobotta K, Crohns C, v. Koch F, Kahlert S, Blokh E, Bauerfeind I, **Konecny G**, Nestle-Krämling C, Möbus V. Dosisdichte und sequentielle Protokolle mit Taxol in der adjuvanten Therapie. In Aktuelle Onkologie, Aktuelle Aspekte in der Therapie solider Tumoren, du Bois A, Bokemeyer C, Gatzemeier U, Lueck HJ (Eds.), 107:34-44, Zuckschwerdt Verlag, 2001
22. Untch M, Ditsch N, Bauerfeind I, Kahlert S, Sorokina Y, von Koch F, Langer E, **Konecny G**, Hepp H. Stellenwert von Taxol® in der adjuvanten Therapie. In Aktuelle Onkologie, 116:1-14 Zuckschwerdt Verlag, 2002
23. Untch M, Crohns C, **Konecny GE**. Anti-HER/2 Therapie beim Mammakarzinom In: Antikörpertherapie in der Hämatologie und Onkologie UNI-MED Verlag, Science, Kneba, Dreger, Pantel (Eds.), 148-156, 2002
24. **Konecny G**, Arboleda J, Slamon DJ, Pegram M. Inhibition of the HER-2/neu Oncogene: a translational research model for the development of future targeted therapies. In Oncogene-Directed Therapies, Rak JW (Ed.), Humana Press Inc., Totowa, NJ, 131-153, 2003
25. **Konecny GE**, Pegram M, HER2-Überexpression und die Entwicklung einer Therapie mit Trastuzumab (Herceptin®) beim Mammakarzinom. In Diagnostik und Therapie des Mammakarzinoms. State of the Art, Untch M, Sittek H, Bauerfeind I, Reiser M, Hepp H (Eds.), 327-342, 2004
26. **Konecny GE**, Pegram M Tyrosinkinase-Inhibitoren in der Therapie des Mammakarzinoms. In Diagnostik und Therapie des Mammakarzinoms. State of the Art, Untch M, Sittek H, Bauerfeind I, Reiser M, Hepp H (Eds.), 343-346, 2004

REVIEWS

1. **Konecny G**, Untch M. Das Proto-Onkogen c-erbB-2 in der Therapie des Mammakarzinoms. Gynäkol Prax 21:749-754, 1997
2. **Konecny G**, Untch M, Hepp H, New drugs in therapy of breast carcinoma: current status and outlook. Gynakol Geburtshilfliche Rundsch 37(2):54-61, 1997
3. **Konecny G**, Untch M, Pegram M. Herceptin in der Therapie des metastasierten Mammakarzinoms. Gynäkologe 32:624-631, 1999

4. Untch M, von Koch F, Kahlert S, **Konecny G**. Overview of epirubicin-based adjuvant therapy in breast cancer. *Clin Breast Cancer* S41-S45, 2000
5. **Konecny G**, Pegram M. Trastuzumab/chemotherapy combinations in HER2-overexpressing breast cancer: Trials in early stage and advanced disease. *HER2 in Oncology* 3(4) 2-4, 2002
6. **Konecny GE**, Lapatinib: a viewpoint by Gottfried E. Konecny. *Drugs*, 67(14):2109-10, 2007
7. **Konecny GE**. Cyclin-dependent kinase pathways as targets for women's cancer treatment. *Curr Opin Obstet Gynecol*;28(1):42-8, 2016
8. **Konecny GE**, Winterhoff B, Wang C. Gene expression signatures in ovarian cancer: Promise and challenges for patient stratification. *Gynecol Oncol* 141(2):379-85, 2016
9. **Konecny GE**, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. *Br J Cancer* 115(10):1157-1173, 2016
10. Winterhoff B, **Konecny GE**. Targeting fibroblast growth factor pathways in endometrial cancer. *Curr Probl Cancer* 2017; 41(1):37-47
11. Campos MP, **Konecny GE**. The target invites a foe: antibody-drug conjugates in gynecologic oncology. *Curr Opin Obstet Gynecol*. 2018;30(1):44-50.

EDITORIALS

1. **Konecny GE**, Wilson CA, Slamon DJ. Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention? *J Natl Cancer Inst* 95(24):1813-5, 2003
2. **Konecny GE**, Challenges in the development of novel targeted therapies. Editorial. *Breast Care* 2:64-66, 2007
3. **Konecny GE**. Are ABCB1 (P-glycoprotein) polymorphisms clinically relevant in ovarian cancer? - Finally an Answer! *Gynecol Oncol* 2013;131(1):1-2

4. **Konecny GE.** Sequencing efforts help to refine the molecular classification of breast cancer.
Curr Opin Obstet Gynecol 2014;26(1):18-20
5. Fasching PA, **Konecny GE**, Spurdle AB. Biomarkers in Women's Cancers, Gynecology, and Obstetrics.
Biomed Res Int 2014; 602340
6. **Konecny GE.** The path to personalized medicine in women's cancers: challenges and recent advances.
Curr Opin Obstet Gynecol 2015;27(1):45-7
7. **Konecny GE.** Securing global access to innovations in woman's cancer care and control
Curr Opin Obstet Gynecol 2016;28(1):1-3
8. **Konecny GE.** Cancer genomics and clinical practice: how can we close the gap more quickly?
Curr Opin Obstet Gynecol 2017;29(1):1-3
9. **Konecny GE.** Understanding Exceptional Responses to PARP Inhibition in Sporadic Ovarian Cancer.
J Clin Oncol 2017; 10;35(11):1151-1153
10. **Konecny GE.** Fasching P. The potential for precision medicine to improve care and speed the development of new treatments in breast an gynecologic malignancies.
Curr Opin Obstet Gynecol 2019, in press
11. Konecny GE. Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer.
Lancet Oncol 2019 May;20(5):612-614.

ABSTRACTS (Selection)

1. Untch M, Blaibl A, Sevin BU, **Konecny G**, Nestle-Krämling C, Hepp H. Prätherapeutische in vitro-Chemosensitivität bei gynäkologischen Tumoren. Einsatz des ATP-CSA (ATP-Chemosensitivitätsassay). *Arch Gynecol Obstet* 254:1074-1076, 1993
2. Untch M, Nestle-Krämling C, **Konecny G**, Harbeck N, Funke I, Hepp H. Prognostic significance of tumor cells in bone marrow in early breast cancer. *Breast Cancer Res Treat* 27:157, 1993

3. Untch M, **Konecny G**, Nestle-Krämling C. Dose intensive breast cancer treatment with G-CSF support. *Ann Hematol* 67:Suppl.2, 67, #18, 1993
4. Untch M, Meier W, **Konecny G**, Nestle-Krämling C, Baumgartner L, Kimmig R, Korell M. Gynecologic tumor chemosensitivity assay (TCA) using ATP bioluminescence. Correlation of in vitro - in vivo results. *Ann Oncol* 5 Suppl.8-10, #45, 1994
5. Untch M, Böttcher B, Schneider P, Nestle-Krämling C, **Konecny G**, Funke I, Hepp H. Tumor proteases in primary tumors and tumor cells in the bone marrow of breast cancer patients. Correlation to established prognostic factors. *Breast Cancer Res Treat* 32:Suppl.1, 89, 1994
6. Untch M, Nestle-Krämling C, **Konecny G**, Funke I. New prognostic factors in early breast cancer. *Obstet Gynecol* 46:Suppl.1, 210, 1994
7. Untch M, Andreotti PE, Nestle-Krämling C, **Konecny G**. Prediction of resistance and sensitivity in gynecologic tumors after primary therapy. The tumor chemosensitivity assay (TCA) using ATP bioluminescence. *Obstet Gynecol* 46:Suppl.1, 64, 1994
8. Untch M, Sevin BU, Nestle-Krämling C, **Konecny G**, Korell M. Pretherapeutic testing in gynecologic tumors with the ATP-CVA. *J Cancer Res Clin* 120:Suppl.79, 26, 1994
9. Untch M, Andreotti PE, Nestle-Krämling C, **Konecny G**. Clinical applications of chemosensitivity testing. *J Tumor Marker Oncol* 9:13, 1994
10. Nestle-Krämling C, **Konecny G**, Untch M Leuprorelinacetat (LPA) in the treatment of premenopausal metastatic breast cancer. *Clin Cancer Res* 120:Suppl 160, 1994
11. **Konecny G**, Nestle-Krämling C, Untch M. Tolerance and toxicity of high dose epirubicin, cyclophosphamide in the treatment of high risk early stage breast cancer. *Clin Cancer Res* 120:Suppl 121, 1994
12. Nestle-Krämling C, Untch M, Hagen D, Fields K, Funke I, **Konecny G**. Detection of tumor cells in the bone marrow of breast cancer patients by cytokeratin 19-reverse transcriptase-polymerase chain reaction (RT-PCR). *Eur J Cancer* 31a:Suppl.3, 35, #74, 1995
13. **Konecny G**, Untch M, Bauerfeind I, Piche E, Nestle-Krämling C. Adjuvant high dose epirubicin and cyclophosphamide with G-CSF support in patients with locally advanced breast cancer. *Eur J Cancer* 31a:Suppl.3, 36, #79, 1995
14. Untch M, Nestle-Krämling C, **Konecny G**, Hepp H Eine Arbeitshypothese zur Metastasierungskaskade beim Mammakarzinom. *Arch Gynecol Obstet* 260:402 #V1.AH.07, 1996

15. **Konecny G**, Crohns C, Meier W, Untch M. Carboplatin-Endoxan-Resistenz beim Ovarialkarzinom: Korrelation mit dem prätherapeutischen ATP Tumorchemosensitivitätsassay (ATP-TCA). *Arch Gynecol Obstet* 258:Suppl.1, 18, 1996
16. Lück HJ, Thomssen C, du Bois A, Lisboa B, Untch M, **Konecny G**, Kühnle H, Jänicke F, Meerpohl HJ, Jonath W, Hecker D, Diergarten K. Phase II-study of paclitaxel and epirubicin as first line therapy in patients with metastatic breast cancer. *Breast Cancer Res Treat* 37:88, 1996
17. Untch M, Nestle-Krämling C, **Konecny G**, Bauerfeind I, Fuchs W, Kreienberg R. Clinical efficacy and side effects of leuprorelin acetat in premenopausal patients with metastatic breast cancer. *Gynecol Endocrinol* 10 Suppl.1:70, #140, 1996
18. **Konecny G**, Thomssen C, Fuegger T, et al. Locally advanced breast cancer: results of an adjuvant study with dose intensified epirubicin and cyclophosphamide with G-CSF support. *Breast Cancer Res Treat* 37:79 (abstr.),1996.
19. Untch M, Crohns C, **Konecny G**, Meier W, Kurbacher C, Andreotti PE, Bruckner HW. Correlation of in vitro tumor chemosensitivity assay with outcome in ovarian cancer patients given carboplatin and cyclophosphamide. *Proc ASCO*, abstr. 841, 1996
20. **Konecny G**, Blokh E, Nestle-Krämling C, Bauerfeind I, Böttcher B, Untch M. ATP tumor chemosensitivity assay in breast cancer. A preliminary report for in vitro drug testing. *Breast Cancer Res Treat* 46:414,1997
21. Thomssen C, Untch M, Schill E, Sattler D, **Konecny G**, Bauerfeind I, Jänicke F, Graeff H. Dose-intensified versus standard chemotherapy in high-risk breast cancer patients: preliminary data of a randomized trial. *Eur J Cancer* 9(8):33, 1997

22. Untch M, Thomssen C, **Konecny G**, Lebeau A, Dettmar P, Sattler D, Kahlert S, Graeff H, Jänicke F, Hepp H c-erbB-2. Überexpression und Ansprechen einer dosisintensivierten Therapie mit Epirubicin und Cyclophosphamid beim Mammakarzinom. *Arch Gynecol Obstet* 261:Suppl.1 P2.04.01, 1998
23. **Konecny G**, Kuhn W, Sattler D, Thomssen Chr, Bauknecht T, Eidtmann H, Moebus V, du Bois A, Schulze R, Jackisch C, Schroeder W, von Minckwitz G, Richter B, Koehler G, Untch M, Lueck H.J. Epirubicin/Paclitaxel (ET) vs Epirubicin/ Cyclophosphamide (EC) as first line chemotherapy (CRx) in metastatic breast cancer (MBC): toxicity data and overall response rates of a randomized multi-center trial. *Breast Cancer Res Treat* 222, 1998
24. Kahlert S, **Konecny G**, Boettcher B, Bauerfeind I, Nestle-Krämling C, Untch M. Response to adjuvant systemic treatment in breast cancer patients with elevated uPA and PAI-1. *Breast Cancer Res Treat* 117, 1998
25. Thomssen C, Untch M, Schill E, Sattler D, **Konecny G**, Kahlert S, Hepp H, Graeff H, Jänicke F. Dose-intensive adjuvant chemotherapy of high-risk breast cancer patients: first results of a prospective randomized trial. *J Cancer Res Clin* 124:Suppl.R123, 1998
26. **Konecny G**, Herrmann K, Frey C, Kahlert S, Sittek H, Reiser M, Untch M. Intra-arterial chemotherapy in patients with regional breast cancer recurrences. *J Cancer Res Clin* 124:Suppl.R117, 1998
27. Kahlert S, **Konecny G**, Gilster TJ, Weishaup A, Klink F, Kurbacher CM, Untch M. Preliminary results of carboplatin (C) and paclitaxel (P) in advanced anthracycline refractory breast cancer. *J Cancer Res Clin* 124:Suppl.R57, 1998
28. Kahlert S, Boettcher B, **Konecny G**, Bauerfeind I, Nestle-Kraemling C, Untch M. Urokinase-like plasminogenactivator (uPA) and plasminogenactivator-inhibitor type 1 (PAI-1) in primary breast cancer – Predictive markers for tamoxifen resistance? *Eur J Cancer* 34:Suppl.5, 82, 1998
29. **Konecny G**, Thomssen C, Untch M, Kahlert S, Kuhn W, Sattler D, Piche E, Lebeau A, Dettmar P, Graeff H, Jänicke F. Randomised adjuvant trial comparing two dose intensities of epirubicin and cyclophosphamide (EC) in high-risk breast cancer. *Eur J Cancer* 34:Suppl.5, 30, 1998
30. Thomssen C, Untch M, **Konecny G**, Lebeau A, Dettmar P, Sattler D, Kuhn W, Kahlert S, Hepp H, Graeff H, Jänicke F. Lack of correlation between c-erbB-2 overexpression and the effect of dose-intensification of adjuvant chemotherapy in high-risk breast cancer patients. *Eur J Cancer* 34:Suppl.5, 30, 1998

31. Nestle-Krämling C, Kahlert S, **Konecny G**, Bauerfeind I, Böttcher B, Untch M. Lokalrezidive beim Mammakarzinom – Abhängigkeit von Prognosefaktoren und chirurgischer Radikalität. *Arch Gynecol Obstet* 261:Suppl.1, P2.07.02, 1998
32. Böttcher B, Kahlert S, **Konecny G**, Bauerfeind I, Nestle-Krämling C, Untch M, Hepp H. Plasminogenaktivator vom Urokinasetyp (uPA) und Plasminogenaktivator-Inhibitor (PAI-1) beim Mammakarzinom: Prädiktive Faktoren für Hormonresistenz? *Arch Gynecol Obstet* 261:Suppl.1, P2.06.11, 1998
33. Bauerfeind I, **Konecny G**, Nestle-Krämling C, Lebeau A, Sörensen S, Böttcher B, Kahlert S, Untch M. Das Ductale-Carcinoma-in-situ der Brust (DCIS) und c-erbB-2 Überexpression: eine 10-Jahres-Analyse. *Arch Gynecol Obstet* 261:Suppl.1, P2.04.04, 1998
34. **Konecny G**, Sattler D, Kahlert S, Lebeau A, Thomssen C, Kuhn W, Graeff H, Hepp H, Untch M. c-erbB-2 Überexpression und Metastasierungspotential beim primären Mammakarzinom. *Arch Gynecol Obstet* 261:Suppl.1, P2.0408, 1998
35. **Konecny G**, Thomssen C, Kahlert S, Untch M. Dose Intensification in the Adjuvant Treatment of Breast Cancer - Overview of current Standards and New Perspectives. *Hormone Therapy in Breast Cancer* 58-67, 1998
36. **Konecny G**, Thomssen C, Untch M, Lebeau A, Kahlert S, Sattler D, Piche E, Dettmar P, Kuhn W, Jänicke F Effect of selected Prognostic markers on high risk Stage II and III breast cancer treated in a randomized dose-intensified protocol. *Proc ASCO* 17, 1998
37. Untch M, **Konecny G**, Lebeau A, Thomssen C, Kahlert S, Sattler D, Piche E, Jänicke F. Dose-intensification (DI) and c-erbB-2 overexpression in anthracycline-based adjuvant treatment of high risk breast cancer. *Proc ASCO* 17, 1998
38. **Konecny G**, Thomssen C, Lebeau A, et al. Effect of selected prognostic markers on high risk stage II and III breast cancer treated in a randomised dose-intensified adjuvant protocol. *Proc ASCO* 17, abstr. 584, 1998.
39. **Konecny G**, Kuhn W, Sattler D, Thomssen Chr, Bauknecht T, Eidtmann H, Moebus V, du Bois A, Schulze R, Jackisch C, Schroeder W, von Minckwitz G, Richter B, Koehler G, Untch M, Lueck HJ. Epirubicin/Paclitaxel (ET) vs Epirubicin/ Cyclophosphamide (EC) as first line chemotherapy (CRx) in metastatic breast cancer (MBC): toxicity data and overall response rates of a randomized multi-center trial. *Breast Cancer Res Treat*, Abstract #222, 1998
40. **Konecny G**, Thomssen C, Untch M, Kahlert S, Kuhn W, Sattler D, Piche E, Lebeau A, Dettmar P, Graeff H, Jänicke F. Randomised adjuvant trial comparing two dose intensities of epirubicin and

- cyclophosphamide (EC) in high-risk breast cancer. *Eur J Cancer* 34 (Suppl 5):S30, 1998
41. **Konecny G**, Thomssen C, Untch M, Lebeau A, Kahlert S, Sattler D, Piche E, Dettmar P, Kuhn W, Jänicke F. Effect of selected prognostic markers on high risk stage II and III breast cancer treated in a randomized dose-intensified protocol. 34th Annual Meeting of the ASCO, Los Angeles, pp. 16-19, 1998, *Proc ASCO* 1998
 42. Salat C, Menzel H, **Konecny G**, et al. Myeloablative chemotherapy, stem cell transplantation, T-cell reinfusion and bispecific antibodies in patients with metastatic breast cancer: A phase I trial. *Proc ASCO* 17, Abstr. 664, 1998.
 43. Bauerfeind I, Kahlert S, **Konecny G**, Nestle-Krämling C, Böttcher B, Untch M. The influence of lateral or medial tumor location on the prognosis of early breast cancer – a retrospective analysis of 840 patients. *Breast Cancer Res Treat* 57:421, 1999
 44. Kahlert S, **Konecny G**, Nestle-Krämling C, Bauerfeind I, Boettcher B, Untch M. Extent of Axillary Lymph Node Dissection – A Source of Misinterpretation but Not a Prognostic Factor. *Proc ASCO* 18:76a 287, 1999
 45. Blokh E, Crohns C, **Konecny G**, Untch M. Einsatz des ATP-TCA im Rahmen neoadjuvanter Therapieprotokolle beim Mammakarzinom. *Gynäkol Geburtshilfliche Rundsch* 39(2):A14, 1999
 46. **Konecny G**, Pegram M, Beryt M, Untch M, Slamon DJ. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression. *Breast Cancer Res Treat* 57(1):467 (abstr.), 1999.
 47. **Konecny G**, Pegram M, Buller R, Nielsen LL, Horowitz J, Karlan BY, Slamon DJ. Preclinical and clinical studies of combinations of chemotherapy with p53 tumor suppressor gene for ovarian cancer. *Eur J Cancer* 35 (Suppl 5), Abstract #74, 1999
 48. **Konecny G**, Pegram M, Beryt M, Untch M, Slamon DJ. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression. *Breast Cancer Res Treat* 57(1):467 (abstract), 1999
 49. Bauerfeind I, Hagen D, **Konecny G**, Kahlert S, Boettcher G, Nestle-Krämling C, Untch M. Elevated Cytosol Vascular Endothelial Growth Factor (VEGF) Showed a Significant Influence on Outcome: Analyses of 173 Patients with Stage I and II Breast Cancer. *Breast Cancer Res Treat* 64:121, 2000
 50. Behrens K, Thomssen C, Kahlert S, Sattler D, Kuhn W, Oberlechner E, Lebeau A, Dettmer P, **Konecny G**, Jaenicke F, Untch M.

Traditional and New Prognostic Factors in Locally Advanced Breast Cancer. *Breast Cancer Res Treat* 64:143, 2000

51. von Koch F, Kahlert S, Sobotta K, Crohns C, **Konecny G**, Bauerfeind I, Nestle-Krämling C, Untch M Hemoglobin Values during Neoadjuvant Chemotherapy Using Epirubicin, Paclitaxel Followed by CMF. Results form a Randomized Multicenter Trial. *Breast Cancer Res Treat* 64:265, 2000
52. Hagen DB, Bauerfeind I, **Konecny G**, Kahlert S, Nestle-Kraemling C, Boettcher B, Untch M Vascular Epithelial Growth Factor: Cytosol Levels in Primary Breast Cancer and Correlation to Established Prognostic Factors. *Breast Cancer Res Treat* 64:566, 2000
53. Untch M, Blokh E, Marschner N, Kindler M, Lange OF, **Konecny G**, Golan C, Hurtz HJ, Diel IJ. Comparison of Oral Versus Parenteral Administered Bisphosphonates in Breast Cancer Patients with Bone Metastases. *Breast Cancer Res Treat* 64:358, 2000
54. Crohns C, Untch M, **Konecny G**. Different Bisphosphonates Have Direct Cytotoxic Effects on Three Breast Cancer Cell Lines and Fresh Breast Cancer Tumor Tissue *Proc ASCO* 20, #2005, 2001
55. Untch M, Sobotta K, Kahlert S, Moebus V, Kuhn W, Bastert G, Thomssen C, Muck B, Lueck HJ, Wagner U, Opri F, Kurbacher C, von Koch F, **Konecny G**. Safety and Feasibility of Sequential Dose Dense Epirubicin and Paclitaxel as Neoadjuvant Therapy of Primary Breast Cancer: a Randomized Multicenter Phase III Study. *Proc ASCO* 20, #1863, 2001
56. Untch M, Sobotta K, von Koch F, **Konecny G**, Kahlert S, Bauerfeind I Epirubicin/Taxol in the neoadjuvant treatment of breast cancer. Breast conservation and survival. *J of Japan Surgical Society*, NML3, 25, 2001
57. **Konecny G**, Thomssen C, Pegram M, Lueck H, Untch M, Pauletti G, Dandekar U, Kuhn W, Eidtmann H, DuBois A, Olbricht S, Steinfeld D, Moebus V, v. Minckwitz G, Wang H, Slamon DJ. HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. *Proc ASCO* 20:23a (abstract 88), 2001
58. Untch M, Thomssen C, Kahlert S, Behrens K, Bauerfeind I, Oberlechner E, Harbeck N, **Konecny G**, Jänicke F. Five year results of a randomised multicenter dose intense (DI-EC) study with Epirubicin (E) and Cyclophosphamide (C) in high risk breast cancer patients - a treatment of short duration with comparable efficacy to conventional chemotherapy. *Breast Cancer Res Treat* 25: #641, 2002

59. Untch M, **Konecny G**, Ditsch N Sorokina Y, Möbus V, Muck B, Kuhn W, Bastert G, Werner C, Thomssen C, Wallwiener D, Albert U, Bothmann G, Kreienberg R, Lück HJ. Dose-dense sequential Epirubicin-Paclitaxel as preoperative treatment of breast cancer: Results of a randomised AGO study, *Proc ASCO* 21: #133, 2002
60. Untch M, **Konecny G**, Ditsch N, Sorokina Y, Moebus V, Muck B, Kuhn W, Bastert G, Werner Ch, Thomssen Ch, Wallwiener D, Albert U, Bothmann G, Kreienberg R, Lück H.J. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study. *Proc ASCO* 21:34a (abstract 133), 2002
61. Finn RS, Beryt M, **Konecny GE**, Pegram MD, Slamon DJ. ZD1839 ('Iressa') acts synergistically with chemotherapy in ovarian cancer cells expressing high levels of the epidermal growth factor receptor. *Proc ASCO*, abstr. 1928, 2002
62. **Konecny G**, Finn R, Venkatesan N, Wang HJ, Chen J, Rusnak D, Gilmer T, Berger M, Slamon DJ, Pegram M. The novel dual kinase inhibitor GW572016 demonstrates particular activity in HER2-positive and trastuzumab-conditioned breast cancer cells. *Breast Cancer Res Treat* 82 (1): S171, abstr.:1010, 2003
63. Untch M, Stoeckl D, **Konecny G**, Kreienberg R, Thommsen C, Camara O, Moebus V, Kuehn T, DuBois A, Lueck HJ, Gitsch G, Fasching P. A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in Her2 positive primary breast cancer. *Breast Cancer Res and Treat*, abstr. 1064, 2005
64. Ryan B, **Konecny G**, Kahlert S, Wang HJ, Crown J, Untch M, Pegram M, Slamon DJ, Duffy MJ. Survivin protein expression predicts poor outcome in patients with primary breast cancer. *Proc ASCO*, abstract #547, 2005
65. **Konecny GE**, Finn F, Seshagiri S, DeForge L, Untch M, Wang HJ, Kahlert S, Slamon DJ, Pegram MD Evaluation of TGF- α expression and prevalence of EGFR and HER2 kinase domain mutations in breast cancer. *Breast Cancer Res and Treat*, abstr. 3029, 2005
66. **Konecny GE**, Jones M, Pegram MD, Gilmer TM, Slamon DJ, Podratz KC. Activity of lapatinib (GW572016) a novel EGFR/HER2 kinase inhibitor against endometrial cancer cells. Society of Gynecologic Oncologists, *Gynecologic Oncol* abstr. 83, 2006
67. **Konecny GE**, Untch M, Pauletti G, Apple S, Wang HJ, Moebus V, Muck B, Kuhn W, Lueck HJ, Thomssen C, Pegram MD, Slamon DJ. HER2 gene amplification and response to dose dense sequential epirubicin and paclitaxel as neoadjuvant therapy of primary breast cancer, *Breast Cancer Res Treat*, abstr.:1031, 2006

68. Untch M, **Konecny G**, Moebus V, Bauerfeind I, Thomssen Ch, Harbeck N, Kuhn W, Bothmann G, Wallwiener D, Kreienberg R, Lueck HJ. Significant improvement in disease free and overall survival with neoadjuvant, dose intensified two weekly treatment with anthracycline and taxane in primary breast cancer, including inflammatory disease. Fifty five months median follow up results of a multicenter prospective randomised phase III AGO-trial. *Breast Cancer Res Treat*, abstr.:5052, 2007
69. Winterhoff BJN, Glas R, Manivong K, Guorong E, Hong KL, Dering D, Ginther C, Gostout BS, Cliby W, Podratz KC, Slamon DJ, **Konecny GE**, Activity of dasatinib a novel small molecule kinase inhibitor of both the src and abl proteins in human ovarian cancer cells, Society of Gynecologic Oncologists Annual Meeting 2009, *Gynecologic Oncol* 2009
70. **Konecny GE**, Manivong K, Guorong E, Glas R, Dering J, Anderson L, Ginther C, Velculescu V, Calzone F, Slamon DJ. Preclinical evaluation of AMG479 a fully human insulin-like growth factor receptor-1 (IGFR1) antibody in ovarian cancer cells, Molecular Targets and Cancer Therapeutics, EORTC AACR NCI Meeting Boston 11, 2009. *Clinical Cancer Res* 2009
71. Winterhoff B, Le J, Yin T, Guorong E, Dowdy S, Gostout B, Slamon DJ, Finkler N, Podratz K, **Konecny GE**, Biological effects of NVP-BEZ235, an orally available dual PI3K/mTOR inhibitor, in endometrial cancer cell lines in vitro, Society of Gynecologic Oncologists Annual Meeting 2010, *Gynecologic Oncol* S88, abstr.:220, 2010
72. **Konecny GE**, Winterhoff B, Manivong K, Qi J, Kolorova T, Kalli K, Hartmann L, Cliby W, Finkler N, Slamon DJ, PD 0332991, a selective CDK4/6 inhibitor, preferentially inhibits growth of ovarian cancer cells with high Rb and low p16 (CDKN2A) expression. Society of Gynecologic Oncologists Annual Meeting 2010, *Gynecologic Oncol* S138, abstr.:356, 2010
73. Kolarova T, Winterhoff B, Qi J, Manivong K, Chalukya M, Kalli K, Hartmann L, Cliby W, Slamon DJ, **Konecny GE**, PD 0332991, a selective CDK 4/6 inhibitor, preferentially inhibits growth of ovarian cancer cells with high Rb and low p16 (CDKN2A) expression. Proceedings of the 101st Annual Meeting of the *American Association for Cancer Research* 2010, abstr.: 25
74. **Konecny GE**, Winterhoff B, Guorong E, Qi J, Le J, Shi M, Dugan M, Linnartz R, Finn RS, Slamon DJ, Dovitinib (TKI258), a multikinase inhibitor of FGFR, PDGFR, and VEGFR tyrosine kinases, induces growth inhibition in endometrial carcinoma cells. Proceedings of the 102st Annual Meeting of the *American Association for Cancer Research* 2011, abstr.: 3589

75. Davidowitz R, Iwanicki M, Selfors L, **Konecny GE**, Dering J, Slamon DJ, Brugge J. Identification of mechanism involved in mesothelial clearance by ovarian tumor spheroids. Proceedings of the 102st Annual Meeting of the American Association for Cancer Research 2011, abstr.: 4751
76. Loibl S, von Minckwitz G, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, **Konecny GE**, Denkert C, Nekljudova V, Mehta K, Untch M. pCR as a Surrogate in HER2-Positive Patients Treated with Trastuzumab. AACR San Antonio Breast Cancer Symposium 2011, abstr.: S5-4
77. von Minckwitz G, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Hilfrich J, Jackisch C, Gerber B, Barinoff J, Huober J, Hanusch C, **Konecny GE**, Fett W, Stickeler E, Harbeck N, Mehta K, Loibl S, Untch M. Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane +/- Trastuzumab Containing Chemotherapy. AACR San Antonio Breast Cancer Symposium 2011, abstr.: PD07-05
78. Winterhoff B, Haluska P, Kalli K, Cliby W, Gostout B, Oberg A, Maurer M, Hartmann L, Slamon DJ, **Konecny GE**. Insulin-like growth factor receptor 1 pathway signature correlates with adverse clinical outcome in ovarian cancer. Society of Gynecologic Oncology 2011, Gynecologic Oncology, Volume 120, Supplement 1, 2011, S71-S72
79. **Konecny GE**, Finkler N, Lee P, Yovine A, Liu A, Sen P, Squires M, Kay A. A multicenter, nonrandomized, open-label, single-arm phase 2 trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer. Society of Gynecologic Oncology 2012, Gynecologic Oncology, Volume 125, Supplement 1, 2012, S80
80. **Konecny GE**, Finkler N, Garcia A, Raspagliesi F, Lopez CM, McCollum M, Jesus Rubio M, Squires M, Pirota N, Upalawanna A, Yovine AJ, Rocconi RP. Dovitinib as second-line therapy in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or non-mutated advanced and/or metastatic endometrial cancer (EC): A single-arm, multicenter, phase II study. American Society of Clinical Oncology (ASCO), J Clin Oncol 31, 2013 (suppl; abstr TPS5616)
81. Ray-Coquard I, Haluska P, O'Reilly S, Cottu PH, Elit L, Provencher DM, Beckmann MW, Bosserman LD, Jacod S, Houe V, Loberg RD, Glaspy JA, Karlan B, Slamon DJ, **Konecny GE**. A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with

- recurrent platinum-sensitive ovarian cancer. American Society of Clinical Oncology (ASCO), *J Clin Oncol* 31, 2013 (suppl; abstr 5515)
82. **Konecny GE**, Wang C, Winterhoff B, Dering J, Ginther C, Chen HW, Hamidi H, Podratz KC, Cliby W, Dowdy SC, Haluska P, Hartmann LC, Kalli K, Goode EL, Slamon DJ. Prognostic relevance of gene signatures in high-grade serous ovarian carcinoma. American Society of Clinical Oncology (ASCO), *J Clin Oncol* 31, 2013 (suppl; abstr 5510)
83. **Konecny GE**, Haluska P, Janicke F, Sehouli J, Beckmann MW, Feisel G, Pölcher M, Roman L, Rody A, Karlan B, Ray-Coquard IL, Provencher DM, Ben-Baruch N, Cottu PH, Chen H, Wang C, Dering J, Jacod S, Houe V, Slamon DJ. A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 5529)
84. Winterhoff BJN, Kommos S, Oberg AL, Wang C, Riska SM, **Konecny GE**, Fan J, Shridhar V, Goode EL, Kommos F, Du Bois A, Hilpert F, Chien J, Embleton AC, Parmar M, Kaplan RS, Perren T, Hartmann LC, Pfisterer J, Dowdy SC. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 5509)
85. **Konecny GE**, Finkler N, Garcia AA, Lorusso D, Lee P, Rocconi R, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R. Phase 2 study of second-line dovitinib (TKI258) in patients with fibroblast growth factor receptor 2 (FGFR2) –mutated or –nonmutated advanced and/or metastatic endometrial cancer, European Society of Medical Oncology, *Annals of Oncology* 25 (Supplement 5): v1–v41, 2014
86. Swisher E, Brenton J, Kaufmann S, Oza A, Coleman RL, O'Malley, **Konecny GE**, Ma L, Harrel M, Visscher D, Wahner Hendrickson, Lin K, Raponi M, Mann E, Giordano H, Rolfe L, Isaacson J, Yelensky R, Scott C, Allen A, McNeish I. ARIEL2: A phase 2 study to prospectively identify ovarian cancer patients likely to respond to rucaparib. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona 2014
87. McNeish I, Coleman RL, Oza AM, **Konecny GE**, O'Malley D, Kichenadasse G, Scott C, Oaknin A, Floquet A, Park D, Brenton J, Lin K, Shetty S, Raponi M, Isaacson J, Rolfe L, Giordano H, Allen A, Swisher E. Preliminary results of ARIEL2, a phase 2 open-label study to identify ovarian cancer patients likely to respond to rucaparib *Annals of Oncology* 25 (suppl_4): iv305-iv326, 2014

88. McNeish IA, Oza AM, Coleman RL, Scott CL, **Konecny GE**, Tinker A, O'Malley DM, Brenton J, Kristeleit RS, Bell-McGuinn K, Oaknin A, Leary A, Lin K, Raponi M, Giordano H, Goble S, Rolfe L, Yelensky R, Allen AR, Swisher EM. Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. American Society of Clinical Oncology (ASCO)
J Clin Oncol 33, 2015 (suppl; abstr 5508)
89. **Konecny GE**, Wahner Hendrickson AE, Jatoi A, Burton JK, Paroly J, Glaspy JA, Dowdy SC, Slamon DJ. A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer. American Society of Clinical Oncology (ASCO)
J Clin Oncol 34, 2016 (suppl; abstr 5557)
90. Coleman CL, Swisher EM, Oza AM, Scott CL, Giordano H, Lin KK, **Konecny GE**, Tinker A, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard IL, Kaufmann SH, Goble S, Maloney L, McNeish IA. Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC). American Society of Clinical Oncology (ASCO)
J Clin Oncol 34, 2016 (suppl; abstr 5540)
91. Swisher EM, Harrell MI, Lin K, Coleman RL, **Konecny GE**, Tinker AV, O'Malley DM, McNeish I and Kaufmann SH. *BRCA1* and *RAD51C* promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1 Society of Gynecologic Oncology (SGO), *Gynecol Oncol* 2017 (abstract 7)
92. **Konecny GE**, Oza AM, Tinker AV, Coleman RL, O'Malley DM, Maloney L, Wride K, Rolfe L, McNeish I and Swisher EM. Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic *BRCA* mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2. Society of Gynecologic Oncology SGO, *Gynecol Oncol* 2017 (abstract 1)
93. Joshua Millstein, Timothy Budden, Michael Anglesio, Aline Talhouk, Alicia Beeghly-Fadiel, Andrew Berchuck, Georgia Chenevix-Trench, Anna deFazio, Peter A. Fasching, Simon Gayther, María García, Ellen L. Goode, Michelle Henderson, Gottfried E. **Konecny**, Sandra Orsulic, David Huntsman, David Bowtell, Jennifer Doherty, Paul Pharoah, Susan J Ramus. A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.
J Clin Oncol 36, 2018 (suppl; abstr 5583)

94. Essela KG, Behbakhtb K, Laic T, Handd L, Evansa E, Dvoraka JD, Dinge K, **Konecny GE**, Moore KN: PARPi after PARPi in epithelial ovarian cancer, *Society of Gynecologic Oncology Annual Meeting* 2019 (Abstr.7 - Scientific Plenary)
95. Gaya L, Schink JC, Wright JD, Lele SB, Mayor PC, Odunsi K, Hemmerich A, Ngoa N, Secord AA, Hou JY, **Konecny GE**, Santin AD Elvin JA. Targeting *ERBB* family genomic alterations in gynecological malignancies. *Gynecologic Oncology* 2019 (suppl; abstr.1319)
96. Burkett Jr. WC, Moore KN, Holman LL, **Konecny GE**, Cohen JG, Prendergast EN, Odunsi K, Ding K. Exploratory analysis of somatic *BRCA* mutations in endometrial cancer and its clinical implications. *Gynecologic Oncology* 2019 (suppl; abstr 2453)
97. Moore KN, Chambers SK, Hamilton EP, Chen L, Oza AM, Ghamande SA, **Konecny GE**, Plaxe SC, Spitz DL, Geenen JJ, Troso-Sandoval TA, Cragun JM, Imedio ER, Kumar S, Mugundu GM, Lai Z, Chmielecki J, Fields Jones S, Spigel DR, Cadoo KA. Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study. *J Clin Oncol* 37, 2019 (suppl; abstr 5513)
98. Cristea MC, Frankel PH, Synold TW, Mortimer JE, Stewart DB, Wang EW, Jung A, Wilczynski SP, **Konecny GE**, Parungao D, Eng M, Kilpatrick L, Chen Y, Glaser S, Han ES, Dellinger TH, Hakim A, Lee S, Morgan R, Wakabayashi MT. A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC). *J Clin Oncol* 37, 2019 (suppl; abstr 3009)